Anya Scheiss

Bio

Anya’s favorite part of investing is working with entrepreneurs to market-proof ideas, identify early customers, and solve problems during the inevitable pivots along the way. Prior to co-founding Healthy Ventures, Anya led strategy and business development for Cardinal Health's medical services, distribution, and laboratory businesses. Prior to Cardinal Health, Anya was a venture capitalist at Thomas, McNerney & Partners, where she focused on life sciences, mostly in later-stage opportunities. She invested and was a board director or observer in: Virdante Pharma (acquired by Momenta Pharma, Invitae Corp (NYSE: NVTA), Celator Pharma (NASDAQ: CPXX), and Innopharma Inc (acquired by Pfizer Inc). At Thomas, McNerney, Anya saw and participated in the emerging 'digital health’ sector, initially investing in the rise of the genomics services subsector. Before entering the investing arena, Anya held several sales and marketing leadership roles at Medtronic and worked with terrific teams to launch neurological, cardiovascular, and cardiac rhythm products. Prior experiences include implementing HIV/AIDS programs for The Clinton Foundation, consulting with McKinsey as a member of the Pharma & Medical Products and Corporate Finance & Strategy practices, and working as part of the Piper Jaffray biotech equity research team. Prior to it all, she joined a seed-stage startup developing “smart” braces to help patients recover faster following orthopedic surgery. Anya earned a BA cum laude from Princeton University and an MBA with honors from The Wharton School at the University of Pennsylvania.